These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 30621779

  • 1. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, Collichio FA.
    J Immunother Cancer; 2019 Jan 08; 7(1):4. PubMed ID: 30621779
    [Abstract] [Full Text] [Related]

  • 2. Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.
    Maximova N, Maestro A, Zanon D, Marcuzzi A.
    J Immunother Cancer; 2020 Feb 08; 8(1):. PubMed ID: 32066648
    [Abstract] [Full Text] [Related]

  • 3. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA.
    Lancet; 2020 Jun 13; 395(10240):1835-1844. PubMed ID: 32534646
    [Abstract] [Full Text] [Related]

  • 4. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA.
    Ann Oncol; 2017 May 01; 28(5):1137-1144. PubMed ID: 28444112
    [Abstract] [Full Text] [Related]

  • 5. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N, Çelik E, Bagcilar O, Erol BC, Bicki E, Oruc K, Bedir S, Degerli E, Derin S, Demirci NS, Demirelli FH.
    Melanoma Res; 2020 Oct 01; 30(5):477-483. PubMed ID: 32898388
    [Abstract] [Full Text] [Related]

  • 6. DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem.
    Ros J, Muñoz-Couselo E.
    BMJ Case Rep; 2018 Sep 30; 2018():. PubMed ID: 30275021
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
    Grän F, Goebeler M, Gesierich A.
    Eur J Dermatol; 2019 Feb 01; 29(1):107-108. PubMed ID: 30998207
    [No Abstract] [Full Text] [Related]

  • 9. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P.
    Nat Med; 2019 Jun 01; 25(6):929-935. PubMed ID: 31171876
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
    de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B.
    J Transl Med; 2017 Jun 24; 15(1):146. PubMed ID: 28646893
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.
    Eur J Cancer; 2019 Jul 24; 116():207-215. PubMed ID: 31212163
    [Abstract] [Full Text] [Related]

  • 15. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.
    J Am Acad Dermatol; 2014 Dec 24; 71(6):1102-1109.e1. PubMed ID: 25440439
    [Abstract] [Full Text] [Related]

  • 16. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A, Tsai K.
    Oncologist; 2017 Jul 24; 22(7):823-833. PubMed ID: 28526719
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
    Urosevic-Maiwald M, Mangana J, Dummer R.
    Ann Oncol; 2017 Jul 01; 28(7):1673-1675. PubMed ID: 28459947
    [No Abstract] [Full Text] [Related]

  • 19. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.
    Eur J Cancer; 2018 Jul 01; 98():10-16. PubMed ID: 29843107
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.